Search fresh public links, source activity, and post angles for Antibody-Drug Conjugates.
Fresh curated links around Antibody-drug conjugates are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Antibody-drug conjugates (ADCs) have evolved from an elegant scientific concept into one of oncology’s most dynamic therapeutic classes. By fusing the targeting specificity of mono...
In the swiftly evolving landscape of gene therapy, antibody-oligonucleotide conjugates (AOCs) have emerged as a transformative platform primed to revolutionize targeted molecular d...
Discover the emerging class of degrader–antibody conjugates – a modality that is drawing increasing interest from biotech companies. The post When ADCs meet targeted protein degra...
Oncology biotech Akari Therapeutics has announced a partnership with WuXi XDC, an antibody-drug conjugate (ADC) development and manufacturing company, to accelerate Akari’s drug de...
Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate that could have better luck bin...
Mutations engineered into antibodies could help companies developing the next generation of antibody-drug conjugates by providing convenient general-purpose “lock-on” locations for...
AbbVie drug Decnupaz received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This antibody drug conjugate came from AbbVie’s 2023 ImmunoGen acqui...
Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” therapies.
by Melissa C. Calopiz, Jennifer J. Linderman, Greg M. Thurber Antibody-drug conjugates (ADCs) have had remarkable clinical success in recent years with multiple new approvals. How...
Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
Eli Lilly has turned its attention down south with a $300 million biobuck acquisition of Houston-based CrossBridge Bio, aiming to advance its dual-payload antibody-drug conjugate (...
Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer...
Work presented at AACR showed promising clinical benefit and manageable safety of investigational ADC QLS5132 in Phase I trial patients with platinum-resistant ovarian cancer, achi...
When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its own hotly anticipated data on a pair of...
Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better effic...
May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...
Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad co...
Regeneron will marry its antibody capabilities with Parabilis’ stabilized helical peptide or Helicon™ platform, with the goal of developing both Antibody-Helicon™ Conjugates...
Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his days in his backyard, sketching out designs for new antibody-drug conjugates with a friend. Now, he’s sharing with...
Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple cancer medicines already in clinical testing.
Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies. The companies said Tubul...
In the relentless battle against HER2-positive breast cancer, a groundbreaking breakthrough is emerging from the cutting-edge intersection of radiopharmaceuticals and targeted ther...
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform
Gilead has struck a deal to buy Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward p...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.